Interviews

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses a study of cobimetinib plus paclitaxel in triple-negative breast cancer (TNBC).

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses results of studies that investigated nivolumab and pembrolizumab in head and neck cancer.

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the current state of liver-directed therapy in metastatic colorectal cancer. 

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses challenges currently facing the ovarian cancer field.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses immune targeting in ovarian cancer.

Matthew Galsky, MD, professor of Medicine at the Mount Sinai School of Medicine, discusses results of a study examining nivolumab monotherapy in metastatic bladder cancer.

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses a clinical trial investigating chemotherapy with durvalumab and tremelimumab in patients with non-small cell lung cancer (NSCLC).

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of<em> T790M </em>in <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC).

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer.&nbsp;

Adam M. Brufsky, MD, PhD, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Philip A. Philip, MD, PhD, professor of oncology and pharmacology, Karmanos Cancer Institute, Wayne State University, discusses how researchers in the pancreatic cancer field can learn from recent negative clinical trials.

Salah-Eddin Al-Batran, MD, medical oncologist and Director at the Institute of Clinical Cancer Research, Frankurt, Germany, discusses the findings of a study of paclitaxel with everolimus in gastric cancer.

Stefani Spranger, PhD, discusses how the presence or absence of CD8-positive T cells can affect treatment approaches for patients with melanoma.

Eileen M. O&rsquo;Reilly, MD, discusses results of a randomized phase II trial of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer.

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.

Cecile Pizot, a biostatistician in Epidemiology at the International Prevention Research Institute, discusses a study that examined breast cancer mortality rates across 47 countries.

Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the&nbsp;Breast International Group 1-98 study.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.

Tanios Bekaii-Saab, MD, professor of Medicine at Mayo Clinic,&nbsp;discusses optimizing sequencing beyond disease progression in colorectal cancer (CRC).

Nicolas Girard, MD, discusses how to maximize the clinical benefit of&nbsp;crizitonib (Xalkori) in non-small cell lung cancer (NSCLC).&nbsp;

Geoffrey Sklar, MD,&nbsp;Chief Medical Officer, Chesapeake Urology Associates, discusses the possibility for immunotherapy as a neoadjuvant treatment in bladder cancer.

Kevin R. Kelly, MD, PhD, discusses the differences seen between ethnic groups in multiple myeloma diagnosis and response to treatment.

Sibylle Loibl, MD, PhD,&nbsp;co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.&nbsp;

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital M&uuml;nster, discusses prognostic factors influencing local control in Ewing sarcoma.

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses key considerations in the selection of frontline therapy in metastatic colorectal cancer.